BIA 3-202, a novel catechol-O-methyltransferase inhibitor, enhances the availability of L-DOPA to the brain and reduces its O-methylation.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  European Journal of Pharmacology

• Publication date

  2001-05-18

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/S0014-2999(01)01020-2PMID 11412836
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone

  2004cited by this paper
• The O-methylated derivative of L-DOPA, 3-O-methyl-L-DOPA, fails to inhibit neuronal and non-neuronal aromatic L-amino acid decarboxylase.

  2000cited by this paper
• New, selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson's disease.

  1999cited by this paper
• History of levodopa and dopamine agonists in Parkinson's disease treatment

  1998cited by this paper
• Tolcapone in stable Parkinson's disease

  1997cited by this paper
• Tolcapone in stable Parkinson's disease: Efficacy and safety of long-term treatment

  1997cited by this paper
• Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-dopa and dopamine in rats.

  1995cited by this paper
• Effects of tolcapone in Parkinson's patients taking L‐dihydroxyphenylalanine/carbidopa and selegiline

  1995cited by this paper
• Integrated pharmacokinetics and pharmacodynamics of the novel catechol‐O‐methyltransferase inhibitor tolcapone during first administration to humans

  1995cited by this paper
• Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients

  1994cited by this paper
• Clinical Potential of Catechol-OMethyltransferase (COMT) Inhibitors as Adjuvants in Parkinson’s Disease

  1994cited by this paper
• Improved Therapy of Parkinson's Disease with Tolcapone, a Central and Peripheral COMT Inhibitor with an S‐Adenosyl‐L‐Methionine‐Sparing Effect

  1994cited by this paper
• Potent COMT inhibition by Ro 40-7592 in the periphery and in the brain. Preclinical and clinical findings.

  1993cited by this paper
• Catechol‐O‐methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients

  1993cited by this paper
• Effects of COMT inhibitors on striatal dopamine metabolism: a microdialysis study.

  1992cited by this paper
• Extracellular Concentrations of Dopamine and Metabolites in the Rat Caudate After Oral Administration of a Novel Catechol‐O‐Methyltransferase Inhibitor Ro 40–7592

  1992cited by this paper
• Different in vivo properties of three new inhibitors of catechol O‐methyltransferase in the rat

  1992cited by this paper
• Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease.

  1990cited by this paper
• Ro 40-7592: inhibition of COMT in rat brain and extracerebral tissues.

  1990cited by this paper
• New selective COMT inhibitors: useful adjuncts for Parkinson's disease?

  1989cited by this paper
• Properties of novel effective and highly selective inhibitors of catechol-O-methyltransferase.

  1988cited by this paper
• Catecholamine metabolism: basic aspects and clinical significance.

  1985cited by this paper

• Neurological and psychiatric management using COMT inhibitors: A review.

  2019cites this paper
• A Screening Strategy for Evaluation of Drug Transport across the Blood-Brain Barrier: Application to Catechol-O-methyltransferase Inhibitors, Dopamine β-hydroxylase Inhibitors and Dibenz[b,f]azepine-5-carboxamide Derivatives

  2018cites this paper
• Pharmacokinetics of opicapone, a third‐generation COMT inhibitor, after single and multiple oral administration: A comparative study in the rat

  2017cites this paper
• Development of a liquid chromatography assay for the determination of opicapone and BIA 9-1079 in rat matrices.

  2016cites this paper
• In‐vivo evaluation of prolonged release bilayer tablets of anti‐Parkinson drugs in Göttingen minipigs

  2011cites this paper
• Biochemistry and pharmacology of catechol-O-methyltransferase inhibitors.

  2010cites this paper
• Toxicology and safety of COMT inhibitors.

  2010cites this paper
• Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.

  2009cites this paper
• Effects of Nebicapone on Levodopa Pharmacokinetics, Catechol-O-methyltransferase Activity, and Motor Fluctuations in Patients with Parkinson Disease

  2008cites this paper
• Pharmacokinetic-Pharmacodynamic Interaction between Nebicapone, a Novel Catechol-O-Methyltransferase Inhibitor, and Controlled-Release Levodopa/Carbidopa 200 mg/50 mg

  2008cites this paper
• Catechol-O-methyltransferase and its inhibitors in Parkinson's disease.

  2007cites this paper
• Neurotoxins and Drugs for the Treatment of Parkinson's Disease. Part I: Neurotoxins, Levodopa, and Agents Influencing Dopamine Metabolism (A Review)

  2005cites this paper
• Microplate screening assay to identify inhibitors of human catechol-O-methyltransferase.

  2004cites this paper
• Pharmacokinetic–Pharmacodynamic Interaction Between BIA 3-202, a Novel COMT Inhibitor, and Levodopa/Carbidopa

  2004cites this paper
• Catechol-O-methyltransferase inhibition in erythrocytes and liver by BIA 3-202 (1-[3,4-dibydroxy-5-nitrophenyl]-2-phenyl-ethanone).

  2003cites this paper
• Molecular modeling and metabolic studies of the interaction of catechol-O-methyltransferase and a new nitrocatechol inhibitor.

  2003cites this paper
• Pharmacokinetic and Pharmacodynamic Profiles of BIA 3–202, a Novel Catechol‐O‐Methyltransferase (COMT) Inhibitor, during Multiple‐Dose Administration to Healthy Subjects

  2003cites this paper
• Kinetic inhibitory profile of BIA 3-202, a novel fast tight-binding, reversible and competitive catechol-O-methyltransferase inhibitor.

  2003cites this paper
• Position of COMT inhibition in the treatment of Parkinson's disease.

  2003cites this paper
• Pharmacokinetic–pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/benserazide

  2003cites this paper
• Comparison of the hepatic safety of catechol-O-methyltransferase inhibitors entacapone and tolcapone with special reference to uncoupling of oxidative phosphorylation

  2003cites this paper
• Pharmacokinetics and Pharmacodynamics of BIA 3-202, a Novel COMT Inhibitor, during First Administration to Humans

  2003cites this paper
• Kinetics and crystal structure of catechol-o-methyltransferase complex with co-substrate and a novel inhibitor with potential therapeutic application.

  2002cites this paper